(237) A shared neoantigen melanoma vaccine formulated with a novel biodegradable liquid polymer
Introduction: Despite advances in immunotherapies, clinical treatments for metastatic melanoma remain limited. A neoantigen peptide mutation found on melanoma tumors, BRAF V600E, is a promising target for vaccines, as it is shared among nearly 50% of all melanoma patients [1]. Our objective is to develop a sustained release formulation of a mutant BRAF peptide vaccine via an injectable depot of a novel biodegradable hydrophobic liquid polymer (named “CAPRO”), aiming to achieve antigen-specific CD8 T cell responses.
Learning Objectives:
understand the concepts and principles of cancer vaccine delivery.
understand the design and application of hydrophobic liquid polymers.
understand how polymers can be utilized in vaccines to optimize antigen-specific immune responses.
Bhushan Munjal, n/a – PostDoc, University of Minnesota; Courtney Erskine, n/a – Sr. Research Technologist, Mayo Clinic; Andrew Goode, n/a – PostDoc, University of Minnesota; Marcus Flowers, n/a – PhD, University of Minnesota; Matthew Block, n/a – Principal Investigator, Mayo Clinic; Vadim Gurvich, n/a – Principal Investigator, University of Minnesota; Raj Suryanarayanan, n/a – Principal Investigator, University of Minnesota; Chun Wang, n/a – Principal Investigator, University of Minnesota
